K121Q polymorphism in the Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 gene is associated with acute kidney rejection

Denise A. Sortica¹,²*, Daisy Crispim¹,²*, Andrea C. Bauer²,³*, Pamela S. Nique¹,²‡, Bruna B. Nicoletto¹,⁴‡, Riciei P. Crestani¹‡, Jennifer T. Staehler¹‡, Roberto C. Manfro³*, Luis H. Canani¹,²*  

¹ Endocrine Division, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil, ² Postgraduate Program in Medical Sciences: Endocrinology, Faculdade de Medicina, Universidade Federal do Rio Grande do Sul, Porto Alegre, Rio Grande do Sul, Brazil, ³ Division of Nephrology, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil, ⁴ Life Science Knowledge Area, Universidade de Caxias do Sul, Caxias do Sul, Rio Grande do Sul, Brazil  

* These authors also contributed equally to this work.  
‡ These authors contributed equally to this work.

Abstract  

The identification of risk factors for acute rejection (AR) may lead to strategies to improve success of kidney transplantation. Ectonucleotidases are ectoenzymes that hydrolyze extracellular nucleotides into nucleosides, modulating the purinergic signaling. Some members of the Ectonucleotidase family have been linked to transplant rejection processes. However, the association of Ectonucleotide Pyrophosphatase / Phosphodiesterase 1 (ENPP1) with AR has not yet been evaluated. The aim of this study was to evaluate the association between the K121Q polymorphism of ENPP1 gene and AR in kidney transplant patients. We analyzed 449 subjects without AR and 98 with AR from a retrospective cohort of kidney transplant patients from Southern Brazil. K121Q polymorphism was genotyped using allelic discrimination-real-time PCR. Cox regression analysis was used to evaluate freedom of AR in kidney transplant recipients according to genotypes. Q allele frequency was 17.6% in recipients without AR and 21.9% in those with AR (P = 0.209). Genotype frequencies of the K121Q polymorphism were in Hardy-Weinberg equilibrium in non-AR patients (P = 0.70). The Q/Q genotype (recessive model) was associated with AR (HR = 2.83, 95% CI 1.08–7.45; P = 0.034) after adjusting for confounders factors. Our findings suggest a novel association between the ENPP1 121Q/Q genotype and AR in kidney transplant recipients.

Introduction  

Kidney transplantation has become the treatment of choice for a substantial proportion of patients with end-stage renal disease. Transplantation has been shown to provide better quality of life and longer life expectancy than dialysis treatment [1, 2]. However, the survival rate in
kidney transplant recipients is significantly lower than age-matched controls in the general population mainly due to recipient’s related factors, that include co-morbidities and duration of dialysis treatments, and transplant-related complications, such as infections, hypertension, diabetes, cancer, and acute rejection (AR) episodes [3, 4]. AR is correlated with progression to chronic allograft dysfunction, which is the most frequent cause of renal transplant failure [5]. AR is a potentially destructive allograft immune response that may occur at any time during the life span of a grafted organ. A number of factors are known to be associated with increased risk of AR, including recipient’s age, ethnicity, HLA sensitization and occurrence of delayed graft function (DGF). However, these factors alone may not fully account for all rejection episodes [6, 7]. Currently the gold standard for AR diagnosis is the allograft biopsy, an invasive procedure with related complications [8]. The development of noninvasive tools that help to predict the risk of AR might ultimately lead to strategies to improve patient and allograft outcomes [9, 10]. In this scenario, DNA polymorphisms that might be predictors of AR are worth to be thoroughly investigated [11].

Ectonucleotidases are ectoenzymes that hydrolyze extracellular nucleotides into nucleosides. They consist of four families, namely, ectonucleoside triphosphate diphosphohydrolases (NTPDases), ectonucleotide pyrophosphatase/phosphodiesterases (NPPs), ecto-5’-nucleotidases and alkaline phosphatases, and they are involved in the modulation of purinergic signaling [12]. Different ectonucleotidases, including NTPDase1 [13] and ecto-5’-nucleotidase, have been associated with chronic allograft rejection [14].

Ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) belongs to the NPP family. This enzyme was first reported as a surface marker of B lymphocytes, being previously called plasma-cell differentiation antigen-1 (PC-1). ENPP1 is a cell membrane protein with an extracellular active site catalyzing the release of nucleoside 5-monophosphatase from nucleotides and their derivatives [15]. This enzyme is expressed in various tissues, including kidney, heart, brain, pancreatic islets, placenta, lung, salivary gland, epididymis, chondrocytes and lymphocytes [15]. It seems to be involved in immune system modulation [16, 17], possibly via degradation of extracellular adenosine triphosphate (ATP) and adenosine generation [18]. It has been shown that the K121Q polymorphism in the ENPP1 gene is a risk factor for diabetes mellitus (DM) [15, 19] and diabetic kidney disease [20, 21], but its association with AR has not been evaluated.

Considering the potential involvement of different ectonucleotidases in transplant rejection, and a possible role of ENPP1 in immune modulation, we hypothesized that polymorphisms in the ENPP1 gene might play a role in the AR process and, if so, could be used as predictor biomarkers of AR. Therefore, the aim of the present study was to evaluate the association between the ENPP1 K121Q polymorphism and AR in a cohort of kidney transplant recipients.

Materials and methods

Study subjects

This nested case-control study was undertaken within a cohort of kidney transplant recipients from a tertiary teaching hospital in Southern Brazil. It was designed in accordance with STROBE and STREGA guidelines for reporting of genetic association studies [22, 23]. Six hundred and thirteen kidney transplant patients were initially recruited from 2002 to 2016. All recipients were followed-up for at least one year after transplantation. Among them, 501 (81.7%) patients were self-defined as white. Considering that the frequency of the ENPP1 K121Q polymorphism differs between ethnic groups [24, 25], we excluded non-white subjects from the study. We also excluded patients without genotype data, biopsy proven acute
antibody-mediated rejection and those who received a previous transplant, corresponding to 10.37% of the total group. Hence, the analyzed sample comprised 449 subjects. Among them, 98 patients had at least one AR episode (cases) and 351 patients did not present AR episodes during follow-up (control group) (S1 Fig).

**Study variables**

Rejections that occurred within the first post-transplant year were diagnosed by an experienced transplant pathologist according to the Banff classification currently available [26–29]. Data were collected retrospectively from kidney transplant electronic records, and included: donor type [living or deceased (with brain death)], recipient and donor age at transplantation, recipient and donor gender, cold ischemia time, underlying kidney disease, number of pregnancies, number of blood transfusions, cytomegalovirus (CMV) and hepatitis C virus (HCV), renal replacement therapy modality, blood pressure (BP) previous to transplant, smoking habits, presence of DM or a family history of this disease, occurrence of DGF (defined by the requirement for hemodialysis in the first post-transplantation week), HLA mismatches, panel reactive antibody (PRA) class I/II, donor specific antibodies (DSA), induction immunosuppressive therapy, maintenance therapy, occurrence of post-transplant DM (PTDM) and time of AR diagnosis. Until 2006, HLA typing of donors and recipients were performed by PCR-SSP (polymerase chain reaction—sequence specific primers) technique [30], after that, the PCR-SSO (PCR—sequence specific oligonucleotide) technique was used [31]. The study was approved by the Ethics Committee of Hospital de Clínicas de Porto Alegre, and all subjects received adequate information about this study and gave their written informed consent.

**Genotyping of the ENPP1 K121Q polymorphism**

Peripheral blood samples were collected from all patients for DNA extraction and genotyping of the ENPP1 K121Q polymorphism. DNA was extracted using a standardized salting-out procedure. Genotyping of the K121Q (A/C) polymorphism (rs1044498) in exon 4 of the ENPP1 gene was performed using primers and probes contained in the Human Custom TaqMan Genotyping Assay 20x (Thermo Fisher Scientific Inc., Waltham, MA, USA). Primer and probe sequences used for genotyping were: 5’-AGCCTCTGTGCCTGTTCAG-3’ (forward primer), 5’-ACACACAGAACTGTAGTTGATGCA-3’ (reverse primer), 5’-AGTCGCCCTTGTCCTT-3’ (VIC probe), and 5’-TCGCCCTGGTCCTT-3’ (FAM probe). All reactions were conducted in 96-well plates, in a total of 5 μl volume using 2 ng of genomic DNA, TaqMan Genotyping Master Mix 1x (Thermo Fisher Scientific Inc.) and Custom TaqMan Genotyping Assay 1x, and ran on the 7500 Fast Real-Time PCR System (Thermo Fisher Scientific Inc.).

**Statistical analyses**

Allelic frequencies were determined by gene counting, and departures from the Hardy–Weinberg equilibrium (HWE) were verified using \( \chi^2 \) test. Allele and genotype frequencies were compared between groups of patients using \( \chi^2 \) tests. Clinical and laboratory characteristics were compared between groups by using unpaired Student’s t-test or \( \chi^2 \), as appropriate. Variables are shown as mean ± SD or absolute numbers (percentages). The magnitude of the associations with AR were estimated using odds ratios (ORs) with 95% confidence intervals (95% CI). Hazard ratio (HR) and 95% CI obtained from a Cox regression model was used to evaluate freedom of AR episodes in patients according to the presence of the 121Q/Q genotype (recessive model). The selection criteria for variables included in the Cox analysis were a well-established association with AR or P values < 0.10 obtained in the univariate Cox regression. In addition, logistic regression analysis was performed to test the independent association of
the ENPP1 K121Q polymorphism with AR, adjusting for the same covariates used in the Cox analysis. Results for which P values were less than 0.05 were considered statistically significant. Statistical analyses were performed using SPSS version 18.0 (SPSS, Chicago, IL).

Results and discussion

Sample description

Among the 449 renal transplant recipients included in this study, 98 presented biopsy proven acute cellular rejection and three hundred and fifty one patients did not have AR episodes (non-AR group). The median time for biopsy-proven AR was 12.5 days (2–329, minimum-maximum values). The main underlying diseases for CKD were: hypertension (22.8%), diabetic nephropathy (11.4%), primary glomerulonephritis (13.9%), and secondary glomerulonephritis (2%). Twenty one percent of the patients had an unknown underlying disease. Patient’s demographic and clinical characteristics are shown in Table 1. There were no significant differences between AR and non-AR groups regarding donor and recipient gender and age, number of blood transfusions CMV, HCV, number of pregnancies, renal replacement therapy modality, smoking habits, presence of DM, donor type, cold ischemia time, hypertension, HLA-A and B, DSA, and PRA class I or II. However, the mean of total HLA-mismatches was higher in the AR group than in the non-AR group (P = 0.011). Likewise, the frequency of patients with 2 HLA-DR mismatches was higher in the AR group than in the non-AR group (P = 0.008). Stratification of patients according to the two techniques used for HLA typing did not change the results. DGF occurred more frequently in the AR group compared to non-AR patients (P = 0.024). Moreover, a lower percentage of recipients with AR received antibody induction therapy with anti-thymocyte globulin (ATG) in comparison with the non-AR group (P = 0.004).

Maintenance immunosuppression was achieved with prednisone, tacrolimus and mycophenolate for 269 patients (50.9%), 97 patients (18.4%) used prednisone, mycophenolate and cyclosporine, and the remaining patients (30.7%) received other combined therapies.

Molecular analyses

Genotype frequencies were in HWE in controls (P = 0.70). The presence of Q/Q genotype was associated with AR assuming either additive (K/K vs. Q/Q; OR = 3.064; 95% CI 1.267–7.408; P = 0.020) or recessive (K/K+K/Q vs. Q/Q; OR = 3.210; 95% CI 1.343–7.673; P = 0.013) inheritance models (Table 2). The Q allele frequency was similar in AR patients compared to non-AR patients (21.9% vs. 17.6%, respectively; P = 0.209).

In a multivariable Cox regression analysis, the ENPP1 121Q allele remained associated with AR in the recessive model (HR = 2.838, 95% CI 1.080–7.457, P = 0.034; Fig 1) adjusting for HLA-DR mismatches, pregnancies, blood transfusions, recipient age, DGF, and induction therapy. In Table 3, we show HRs for each variable included in the Cox regression analysis. Among these variables, only DGF was associated with risk for AR (HR = 2.774, 95% CI 1.273–6.045, P = 0.010), while induction therapy was associated with protection against AR (HR = 0.345, 95% CI 0.158–0.755, P = 0.008). The independent association of the ENPP1 121Q/Q genotype with AR was confirmed by logistic regression analysis adjusting for HLA-DR mismatches, pregnancies, blood transfusions, recipient age, DGF, and induction therapy (OR = 6.41, 95% CI 1.46–28.19, P = 0.014; S1 Table).
Conclusions

Here, we demonstrate, for the first time, the independent association of the ENPP1 K121Q polymorphism with AR in a cohort of white Brazilian kidney transplant patients.

Ectonucleotidases have been shown to modulate local immune responses by lymphocytes, with anti-inflammatory action that occurs, possibly, via degradation of the extracellular ATP.
and generation of adenosine [12, 18, 32, 33]. Members of the NTPDase (CD39) family are cell membrane enzymes that hydrolyze ATP into adenosine diphosphate (ADP) and ADP into adenosine monophosphate (AMP) in three different steps, releasing inorganic phosphate (Pi). Following that, ecto-5'-nucleotidases (CD73) dephosphorylate AMP into adenosine [34, 35]. In contrast, ENPP1 degrades ATP and ADP into AMP in a single step, releasing AMP along with pyrophosphate (PPi) [12]. In the final hydrolyzation step, the extracellular AMP can be hydrolyzed to adenosine and Pi by the effect of either ecto-5'-nucleotidase (CD73) or one of the four alkaline phosphatase isoforms [32] (Fig 2A).

NTPDase1 (CD39) and ecto-5'-nucleotidases (CD73), as major nucleotide metabolizing enzymes, are known to regulate immunity and inflammation and, possibly, to protect against hypoxic and ischemic tissue injuries [36]. Accordingly, CD39 and CD73 can be viewed as "immunological switches" that shift ATP-driven pro-inflammatory immune cell activity towards an adenosine mediated anti-inflammatory state [36]. Poelstra et al [37], studying a murine glomerulonephritis model, indicated that the ecto-5'-nucleotidase has an anti-inflammatory activity in glomerular cells. Therefore, it is conceivable to suppose that ENPP1 might play a role in the inflammatory process of organ transplant rejection. In this context, the 121Q allele that might lead to decreased ENPP1 activity could be a potential AR risk factor. Further experimental studies are needed in order to better clarify the putative role of ENPP1 in AR of organ allografts.

In order to speculate mechanistically on these findings it is important to mention that adenosine, released by ectonucleotidase activities (including ENPP1), is known to be an inhibitory mediator of T effector lymphocytes in various immune diseases [38–40]. CD39 and C73 are expressed on the surface of T regulatory (Treg) cells, converting ATP into adenosine, which acts as a substrate for Treg immunosuppressive and anti-inflammatory activities [41–43]. Therefore, it is possible that the presence of the ENPP1 Q/Q genotype has an indirect negative effect on CD39 e CD73 activities, since mutated ENPP1 will generate less substrate for the other ectonucleotidases in the cascade. This might lead to increased activity of T effector lymphocytes and thus predispose to AR (Fig 2B). To confirm this hypothesis, the functional effect of the Q/Q genotype on ENPP1 activity in kidney transplant patients must be further explored.

It is established that HLA sensitizing events, such as pregnancies, blood transfusions, and prior transplants, might increase the risk of AR [44]. Likewise, donor and recipient characteristics, such as age and ethnicity also influence this outcome [45–47]. Also, HLA mismatches

### Table 2. Frequencies of the ENPP1 K121Q polymorphism between kidney transplant patients with acute rejection (AR) and without acute rejection (non-AR).

| ENPP1 K121Q polymorphism | AR (n = 98) | Non-AR (n = 351) | P value | P value for additive model<sup>a</sup> | P value for dominant model<sup>b</sup> | P value for recessive model<sup>c</sup> |
|---------------------------|------------|----------------|---------|--------------------------------------|-------------------------------------|-------------------------------------|
| Genotype                  |            |                |         |                                      |                                     |                                     |
| Q/Q                       | 10 (10.2)  | 12 (3.4)       | 0.019   | 0.020                                | 0.835                               | 0.013                               |
| K/Q                       | 23 (23.5)  | 100 (28.5)     |         |                                      |                                     |                                     |
| K/K                       | 65 (66.3)  | 239 (68.1)     |         |                                      |                                     |                                     |
| Allele                    |            |                |         |                                      |                                     |                                     |
| Q                         | 0.219      | 0.176          | 0.209   | -                                    | -                                   | -                                   |
| K                         | 0.780      | 0.823          |         |                                      |                                     |                                     |

Data are shown as n (%) or proportion.

<sup>a</sup>Q/Q vs. K/K

<sup>b</sup>QQ/QK vs. KK

<sup>c</sup>QQ vs. KQ/KK. P values were computed by χ² tests for comparisons between groups.

[https://doi.org/10.1371/journal.pone.0219062.t002](https://doi.org/10.1371/journal.pone.0219062.t002)
are a relevant risk factor for rejection [48, 49]. In our sample, only HLA-DR mismatches, occurrence of DGF and induction therapy with ATG were differently distributed between AR and non-AR groups. Noteworthy, the ENPP1 K121Q polymorphism remained highly associated with AR after adjustment for HLA-DR mismatches, pregnancies, blood transfusions, recipient age, DGF, and induction therapy.
ENPP1 K121Q polymorphism is differentially distributed across ethnicities [15, 20]. In this context, some studies showed that the Q allele has an increased prevalence among African-Brazilians [25] and other African descendent populations [50–52]. Based on this knowledge and also because the vast majority of our sample was comprised of white subjects, we evaluated only white subjects in the present study.

The present study has limitations to be acknowledged, including its retrospective design, and being a single center study without a confirmation cohort. However, we believe that the study of the K121Q polymorphism and its relationship with AR is worth evaluation in other populations in order to confirm or deny the present findings.

In conclusion, our findings support an association between the ENPP1 K121Q polymorphism and AR in kidney transplant patients. The precise mechanisms behind this finding are uncertain and need to be further elucidated. Screening of this polymorphism may be useful to

| Variable                              | HR    | (95% CI)     | P value |
|---------------------------------------|-------|--------------|---------|
| Receptors age                         | 0.969 | 0.937–1.003  | 0.071   |
| Pregnancy                             | 1.434 | 0.548–3.758  | 0.463   |
| Blood Transfusion                     | 1.052 | 0.531–2.085  | 0.884   |
| DGF                                   | 2.774 | 1.273–6.045  | 0.010   |
| HLA-DR mismatches (1)                 | 0.648 | 0.280–1.499  | 0.310   |
| HLA-DR mismatches (2)                 | 1.237 | 0.530–2.884  | 0.623   |
| Q/Q genotype (recessive model)        | 2.838 | 1.080–7.457  | 0.034   |
| Induction therapy                     | 0.345 | 0.158–0.755  | 0.008   |

DGF, delayed graft function; HR, hazard ratio; CI, confidence interval.

ENPP1 K121Q polymorphism is differentially distributed across ethnicities [15, 20]. In this context, some studies showed that the Q allele has an increased prevalence among African-Brazilians [25] and other African descendent populations [50–52]. Based on this knowledge and also because the vast majority of our sample was comprised of white subjects, we evaluated only white subjects in the present study.

The present study has limitations to be acknowledged, including its retrospective design, and being a single center study without a confirmation cohort. However, we believe that the study of the K121Q polymorphism and its relationship with AR is worth evaluation in other populations in order to confirm or deny the present findings.

In conclusion, our findings support an association between the ENPP1 K121Q polymorphism and AR in kidney transplant patients. The precise mechanisms behind this finding are uncertain and need to be further elucidated. Screening of this polymorphism may be useful to

![Ectonucleotidases Cascade](https://doi.org/10.1371/journal.pone.0219062.t003)

### Table 3. Multivariate Cox regression analysis of risk factors for AR.

| Variable                              | HR    | (95% CI)     | P value |
|---------------------------------------|-------|--------------|---------|
| Receptors age                         | 0.969 | 0.937–1.003  | 0.071   |
| Pregnancy                             | 1.434 | 0.548–3.758  | 0.463   |
| Blood Transfusion                     | 1.052 | 0.531–2.085  | 0.884   |
| DGF                                   | 2.774 | 1.273–6.045  | 0.010   |
| HLA-DR mismatches (1)                 | 0.648 | 0.280–1.499  | 0.310   |
| HLA-DR mismatches (2)                 | 1.237 | 0.530–2.884  | 0.623   |
| Q/Q genotype (recessive model)        | 2.838 | 1.080–7.457  | 0.034   |
| Induction therapy                     | 0.345 | 0.158–0.755  | 0.008   |

DGF, delayed graft function; HR, hazard ratio; CI, confidence interval.

ENPP1 K121Q polymorphism is differentially distributed across ethnicities [15, 20]. In this context, some studies showed that the Q allele has an increased prevalence among African-Brazilians [25] and other African descendent populations [50–52]. Based on this knowledge and also because the vast majority of our sample was comprised of white subjects, we evaluated only white subjects in the present study.

The present study has limitations to be acknowledged, including its retrospective design, and being a single center study without a confirmation cohort. However, we believe that the study of the K121Q polymorphism and its relationship with AR is worth evaluation in other populations in order to confirm or deny the present findings.

In conclusion, our findings support an association between the ENPP1 K121Q polymorphism and AR in kidney transplant patients. The precise mechanisms behind this finding are uncertain and need to be further elucidated. Screening of this polymorphism may be useful to

![Ectonucleotidases Cascade](https://doi.org/10.1371/journal.pone.0219062.t003)

### Table 3. Multivariate Cox regression analysis of risk factors for AR.

| Variable                              | HR    | (95% CI)     | P value |
|---------------------------------------|-------|--------------|---------|
| Receptors age                         | 0.969 | 0.937–1.003  | 0.071   |
| Pregnancy                             | 1.434 | 0.548–3.758  | 0.463   |
| Blood Transfusion                     | 1.052 | 0.531–2.085  | 0.884   |
| DGF                                   | 2.774 | 1.273–6.045  | 0.010   |
| HLA-DR mismatches (1)                 | 0.648 | 0.280–1.499  | 0.310   |
| HLA-DR mismatches (2)                 | 1.237 | 0.530–2.884  | 0.623   |
| Q/Q genotype (recessive model)        | 2.838 | 1.080–7.457  | 0.034   |
| Induction therapy                     | 0.345 | 0.158–0.755  | 0.008   |

DGF, delayed graft function; HR, hazard ratio; CI, confidence interval.

ENPP1 K121Q polymorphism is differentially distributed across ethnicities [15, 20]. In this context, some studies showed that the Q allele has an increased prevalence among African-Brazilians [25] and other African descendent populations [50–52]. Based on this knowledge and also because the vast majority of our sample was comprised of white subjects, we evaluated only white subjects in the present study.

The present study has limitations to be acknowledged, including its retrospective design, and being a single center study without a confirmation cohort. However, we believe that the study of the K121Q polymorphism and its relationship with AR is worth evaluation in other populations in order to confirm or deny the present findings.

In conclusion, our findings support an association between the ENPP1 K121Q polymorphism and AR in kidney transplant patients. The precise mechanisms behind this finding are uncertain and need to be further elucidated. Screening of this polymorphism may be useful to

![Ectonucleotidases Cascade](https://doi.org/10.1371/journal.pone.0219062.t003)

### Table 3. Multivariate Cox regression analysis of risk factors for AR.

| Variable                              | HR    | (95% CI)     | P value |
|---------------------------------------|-------|--------------|---------|
| Receptors age                         | 0.969 | 0.937–1.003  | 0.071   |
| Pregnancy                             | 1.434 | 0.548–3.758  | 0.463   |
| Blood Transfusion                     | 1.052 | 0.531–2.085  | 0.884   |
| DGF                                   | 2.774 | 1.273–6.045  | 0.010   |
| HLA-DR mismatches (1)                 | 0.648 | 0.280–1.499  | 0.310   |
| HLA-DR mismatches (2)                 | 1.237 | 0.530–2.884  | 0.623   |
| Q/Q genotype (recessive model)        | 2.838 | 1.080–7.457  | 0.034   |
| Induction therapy                     | 0.345 | 0.158–0.755  | 0.008   |

DGF, delayed graft function; HR, hazard ratio; CI, confidence interval.

ENPP1 K121Q polymorphism is differentially distributed across ethnicities [15, 20]. In this context, some studies showed that the Q allele has an increased prevalence among African-Brazilians [25] and other African descendent populations [50–52]. Based on this knowledge and also because the vast majority of our sample was comprised of white subjects, we evaluated only white subjects in the present study.

The present study has limitations to be acknowledged, including its retrospective design, and being a single center study without a confirmation cohort. However, we believe that the study of the K121Q polymorphism and its relationship with AR is worth evaluation in other populations in order to confirm or deny the present findings.

In conclusion, our findings support an association between the ENPP1 K121Q polymorphism and AR in kidney transplant patients. The precise mechanisms behind this finding are uncertain and need to be further elucidated. Screening of this polymorphism may be useful to

![Ectonucleotidases Cascade](https://doi.org/10.1371/journal.pone.0219062.t003)
predict those patients (carriers of Q/Q genotype) more prone to experience rejection and, therefore, may need a more intense vigilance and perhaps more intense immunosuppressive therapy.

Supporting information

S1 Fig. Flowchart. Flowchart showing the strategy used to select patients for inclusion in the study.
(PDF)

S1 Table. Multivariate logistic regression analysis of risk factors for AR.
(DOCX)

S2 Table. Minimal Data Set used for analyses.
(XLS)

Acknowledgments

We would like to thank to Dr. Natália Emerim Lemos from Endocrine Division, Hospital de Clínicas de Porto Alegre, Rio Grande do Sul, that contributed to the improvement of Figs 1 and 2.

Author Contributions

Conceptualization: Denise A. Sortica, Daisy Crispim, Andrea C. Bauer, Roberto C. Manfro, Luis H. Canani.

Data curation: Denise A. Sortica, Daisy Crispim, Andrea C. Bauer, Pamela S. Nique, Bruna B. Nicoletto.

Formal analysis: Denise A. Sortica, Daisy Crispim, Andrea C. Bauer, Roberto C. Manfro, Luis H. Canani.

Funding acquisition: Roberto C. Manfro, Luis H. Canani.

Investigation: Denise A. Sortica, Daisy Crispim, Andrea C. Bauer, Pamela S. Nique, Ricieli P. Crestani, Jennifer T. Staehler.

Methodology: Denise A. Sortica, Daisy Crispim, Andrea C. Bauer, Pamela S. Nique, Bruna B. Nicoletto, Roberto C. Manfro, Luis H. Canani.

Project administration: Denise A. Sortica, Daisy Crispim, Andrea C. Bauer, Roberto C. Manfro, Luis H. Canani.

Resources: Roberto C. Manfro, Luis H. Canani.

Supervision: Roberto C. Manfro, Luis H. Canani.

Visualization: Denise A. Sortica, Daisy Crispim, Andrea C. Bauer, Pamela S. Nique, Bruna B. Nicoletto, Roberto C. Manfro, Luis H. Canani.

Writing – original draft: Denise A. Sortica, Daisy Crispim, Andrea C. Bauer.

Writing – review & editing: Denise A. Sortica, Daisy Crispim, Andrea C. Bauer, Pamela S. Nique, Bruna B. Nicoletto, Roberto C. Manfro, Luis H. Canani.
References

1. Wolfe RA, Ashby VB, Milford EL, Ojo AO, Ettinger RE, Agodoa LY, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999; 341(23):1725–30. https://doi.org/10.1056/NEJM199912023412303 PMID: 10580071

2. Fiebiger W, Mitterbauer C, Oberbauer R. Health-related quality of life outcomes after kidney transplantation. Health Qual Life Outcomes. 2004; 2:2. https://doi.org/10.1186/1477-7552-2-2 PMID: 14713316

3. Harirhan S, Johnson CP, Bresnahan BA, Taranto SE, McIntosh MJ, Stabilein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Engl J Med. 2000; 342(9):605–12. https://doi.org/10.1056/NEJM200003023420901 PMID: 10699159

4. Meier-Kriesche HU, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2004; 4(3):378–83.

5. Joosten SA, Sijpkens YW, van Kooten C, Paul LC. Chronic renal allograft rejection: pathophysiologic considerations. Kidney International. 2005; 68(1):1–13. https://doi.org/10.1111/j.1523-1755.2005.00376.x PMID: 15954891

6. Pallardo Mateu LM, Sancho Calabuig A, Capdevila Plaza L, Franco Esteve A. Acute rejection and late renal transplant failure: risk factors and prognosis. Nephrol Dial Transplant. 2004; 19 Suppl 3:i38–42.

7. Goldfarb-Rumyantcev AS, Naiman N. Genetic predictors of acute renal transplant rejection. Nephrol Dial Transplant. 2010; 25(4):1039–47. https://doi.org/10.1093/ndt/gfp782 PMID: 20106823

8. Townamchai N, Eiam-Ong S. Biomarkers in kidney transplantation: From bench to bedside. World J Nephrol. 2015; 4(5):487–91. https://doi.org/10.5527/wjn.v4.i5.487 PMID: 26558185

9. Lodge DJ, Verma M, Park KJ. Advances of genomic science and systems biology in renal transplantation: a review. Semin Immunopathol. 2011; 33(2):211–8. https://doi.org/10.1007/s00281-011-0243-2 PMID: 21318414

10. Lo DJ, Kaplan B, Kirk AD. Biomarkers for kidney transplant rejection. Nat Rev Nephrol. 2014; 10(4):215–25. https://doi.org/10.1038/nrneph.2013.281 PMID: 24445740

11. Shirley DG, Vekaria RM, Sevigny J. Ectonucleotidases in the kidney. Purinergic Signal. 2009; 5(4):501–11. https://doi.org/10.1007/s11302-009-9152-4 PMID: 19333785

12. Imai M, Takigami K, Guckelberger O, Enjyoji K, Smith RN, Lin Y, et al. Modulation of nucleoside [correction of nucleotide] triphosphate diphosphohydrolase-1 (NTPDase-1)cd39 in xenograft rejection. Mol Med. 51999. p. 743–52.

13. Sortica DA, Crispim D, Zaffari GP, Friedman R, Canani LH. The role of ecto-nucleotide pyrophosphatase/phosphodiesterase 1 in diabetic nephropathy. Arq Bras Endocrinol Metabol. 2011; 55(9):677–85. PMID: 22231969

14. Dumont FJ, Habbersett RC, Coker LZ, Nichols EA, Treffinger JA. High level expression of the plasma cell antigen PC.1 on the T-cell subset expanding in MRL/MpJ-lpr/lpr mice: detection with a xenogeneic monoclonal antibody and alloantisera. Cell Immunol. 1985; 96(2):327–37. PMID: 2943419

15. Lansac G, Dong W, Dubois CM, Benlarbi N, Afonso C, Fournier I, et al. Lipopoly saccharide mediated regulation of neuroendocrine associated proprotein convertase and neuropeptide precursor processing in the rat spleen. J Neuroimmunol. 2006; 171(1–2):57–71. https://doi.org/10.1016/j.jneuroim.2005.09.019 PMID: 16337011

16. Goding JW, Terkeltaub R, Maurice M, Deterre P, Sali A, Belli SI. Ecto-phosphodiesterase/pyrophosphatase of lymphocytes and non-lymphoid cells: structure and function of the PC-1 family. Immunol Rev. 1998; 161:11–26. PMID: 9553761

17. Pizzuti A, Frittitta L, Argiolas A, Baratta R, Goldfine ID, Bozzali M, et al. A polymorphism (K121Q) of the human glycoprotein PC-1 gene coding region is strongly associated with insulin resistance. Diabetes. 1999; 48(9):1881–4. https://doi.org/10.2337/diabetes.48.9.1881 PMID: 10480624

18. Sortica DA, Busco MP, Souza BM, Nicoletto BB, Santer A, Assmann TS, et al. Association between the ENPP1 K121Q Polymorphism and Risk of Diabetic Kidney Disease: A Systematic Review and Meta-Analysis. PLoS One. 2015; 10(3):e0118416 https://doi.org/10.1371/journal.pone.0118416 PMID: 25794151
21. Canani LH, Ng DP, Smiles A, Rogus JJ, Warram JH, Krolewski AS. Polymorphism in ecto-nucleotide pyrophosphatase/phosphodiesterase 1 gene (ENPP1/PC-1) and early development of advanced diabetic nephropathy in type 1 diabetes. Diabetes. 2002; 51(4):1188–93. https://doi.org/10.2337/diabetes.51.4.1188 PMID: 11916943

22. von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandebroucke JP, et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008; 61(4):344–9. https://doi.org/10.1016/j.jclinepi.2007.11.008 PMID: 18313558

23. Little J, Higgins JP, Ioannidis JP, Moher D, Gagnon F, von Elm E, et al. STrengthening the REporting of Genetic Association Studies (STREGA)—an extension of the STROBE statement. Genet Epidemiol. 2009; 33(7):581–98. https://doi.org/10.1002/gepi.20410 PMID: 19278015

24. Keene KL, Mychaleckyj JC, Smith SG, Leak TS, Perlegas PS, Langefeld CD, et al. Association of the distal region of the ectonucleotide pyrophosphatase/phosphodiesterase 1 gene with type 2 diabetes in an African-American population enriched for nephropathy. Diabetes. 2008; 57(4):1057–62. https://doi.org/10.2337/db07-0886 PMID: 18184924

25. Leitao CB, Nabinger GB, Krahe AL, Bolson PB, Gerchman F, Friedman R, et al. The role of K121Q ENPP1 polymorphism in diabetes mellitus and its complications. Braz J Med Biol Res. 2008; 41(3):229–34. https://doi.org/10.1590/s0100-879x2008000300002 PMID: 18176722

26. Racusen LC, Solez K, Colvin RB, Bonsib SM, Castro MC, Cavallo T, et al. The Banff 97 working classification of renal allograft pathology. Kidney international. 1999; 55(2):713–23. https://doi.org/10.1046/j.1523-1755.1999.00299.x PMID: 9987096

27. Solez K, Colvin RB, Racusen LC, Haas M, Sis B, Mengel M, et al. Banff 07 classification of renal allograft pathology: updates and future directions. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2008; 8(4):753–60.

28. Sis B, Mengel M, Haas M, Colvin RB, Halloran PF, Racusen LC, et al. Banff ’09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2010; 10(3):464–71.

29. Loupy A, Haas M, Solez K, Racusen L, Glotz D, Seron D, et al. The Banff 2015 Kidney Meeting Report: Current Challenges in Rejection Classification and Prospects for Adopting Molecular Pathology. American journal of transplantation: official journal of the American Society of Transplantation and the American Society of Transplant Surgeons. 2017; 17(1):28–41.

30. Bunce M, Welsh KI. Rapid DNA typing for HLA-C using sequence-specific primers (PCR-SSP): identification of serological and non-serologically defined HLA-C alleles including several new alleles. Tissue Antigens. 1994; 43(1):7–17. PMID: 7912861

31. Trajanoski D, Didier SJ. HLA typing using bead-based methods. Methods Mol Biol. 2012; 882:47–65. https://doi.org/10.1007/978-1-61779-842-9_4 PMID: 22665228

32. Baqi Y. Ecto-nucleotidase inhibitors: recent developments in drug discovery. Mini Rev Med Chem. 2015; 15(1):21–33. PMID: 25694081

33. Regateiro FS, Cobbold SP, Waldmann H. CD73 and adenosine generation in the creation of regulatory microenvironments. Clin Exp Immunol. 2013; 171(1):1–7. https://doi.org/10.1111/j.1365-2249.2012.04623.x PMID: 23199317

34. Zimmermann H, Zebisch M, Strater N. Cellular function and molecular structure of ecto-nucleotidases. Purinergic Signal. 2012; 8(3):437–502. https://doi.org/10.1007/s11302-012-9309-4 PMID: 22555564

35. Lazarewski ER, Boucher RC, Harden TK. Mechanisms of release of nucleotides and integration of their action as P2X- and P2Y-receptor activating molecules. Mol Pharmacol. 2003; 64(4):785–95. https://doi.org/10.1124/mol.64.4.785 PMID: 14500734

36. Antonioli L, Pacher P, Vizi ES, Haskó G. CD39 and CD73 in immunity and inflammation. Trends Mol Med. 2013; 19(6):355–67. https://doi.org/10.1016/j.molmed.2013.03.005 PMID: 23601906

37. Poelstra K, Heynen ER, Balier JF, Hardonk MJ, Bakker WW. Modulation of anti-Thy1 nephritis in the rat by adenine nucleotides. Evidence for an anti-inflammatory role for nucleotidases. Lab Invest. 1992; 66(5):555–63. PMID: 15334392

38. Birch RE, Polmar SH. Adenosine induced immunosuppression: the role of the adenosine receptor—adenylate cyclase interaction in the alteration of T-lymphocyte surface phenotype and immunoregulatory function. Int J Immunopharmac. 1986; 8(3):329–37. PMID: 2420210

39. Chhabra P, Linden J, Lobo P, Okusa MD, Brayman KL. The immunosuppressive role of adenosine A2A receptors in ischemia reperfusion injury and islet transplantation. Curr Diabetes Rev. 2012; 8(6):419–33. PMID: 22934547
40. Yamaguchi H, Maruyama T, Urade Y, Nagata S. Immunosuppression via adenosine receptor activation by adenosine monophosphate released from apoptotic cells. Elife. 2014; 3:e02172. https://doi.org/10.7554/eLife.02172 PMID: 24668173

41. Burnstock G, Boeynaems JM. Purinergic signalling and immune cells. Purinergic Signal. 2014; 10 (4):529–64. https://doi.org/10.1007/s11302-014-9427-2 PMID: 25352330

42. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med. 2007; 204 (6):1257–65. https://doi.org/10.1084/jem.20062512 PMID: 17502665

43. Ernst PB, Garrison JC, Thompson LF. Much ado about adenosine: adenosine synthesis and function in regulatory T cell biology. J Immunol. 2010; 185(4):1993–8. https://doi.org/10.4049/jimmunol.1000108 PMID: 20686167

44. Huber L, Lachmann N, Durr M, Lieinfeld L, Neumayer HH, et al. Identification and therapeutic management of highly sensitized patients undergoing renal transplantation. Drugs. 2012; 72(10):1335–54. https://doi.org/10.2165/11631110-000000000-00000 PMID: 22747448

45. Chen GD, Gu JL, Zhang XD, Qiu J, Wang CX, Chen LZ. Donor factors predictive for poor outcomes of living donor kidney transplantation. Transplant Proc. 2013; 45(4):1445–8. https://doi.org/10.1016/j.transproceed.2012.11.015 PMID: 23726593

46. Brown KL, Doshi MD, Singh A, Mehta K, Morawski K, Cincotta E, et al. Does donor race still make a difference in deceased-donor African-American renal allograft recipients? Am J Surg. 2010; 199(3):305–9; discussion 9. https://doi.org/10.1016/j.amjsurg.2009.08.025 PMID: 20226900

47. Schold JD, Srinivas TR, Braun WE, Shoskes DA, Nurko S, Poggio ED. The relative risk of overall graft loss and acute rejection among African American renal transplant recipients is attenuated with advancing age. Clin Transplant. 2011; 25(5):721–30. https://doi.org/10.1111/j.1399-0012.2010.01343.x PMID: 20964717

48. Tonato EJ, Sesso RC, Piveta V, Pestana JOM. Fatores que influenciam a sobrevida de transplantes renais com boa função renal ao final do 1º ano. J Bras Nefrol 1998; 20(1):10.

49. Lin WH, Chadban SJ, Clayton P, Budgeon CA, Murray K, Campbell SB, et al. Human leukocyte antigen mismatches associated with increased risk of rejection, graft failure, and death independent of initial immunosuppression in renal transplant recipients. Clin Transplant. 2012; 26(4):E428–37. https://doi.org/10.1111/j.1399-0012.2012.01654.x PMID: 22672477

50. Morrison JA, Gruppo R, Glueck CJ, Stroop D, Fontaine RN, Wang P, et al. Population-specific alleles: the polymorphism (K121Q) of the human glycoprotein PC-1 gene is strongly associated with race but not with insulin resistance in black and white children. Metabolism. 2004; 53(4):465–8. PMID: 15045693

51. Chandalia M, Grundy SM, Adams-Huet B, Abate N. Ethnic differences in the frequency of ENPP1/PC1 121Q genetic variant in the Dallas Heart Study cohort. J Diabetes Complications. 2007; 21(3):143–8. https://doi.org/10.1016/j.jdiacomp.2006.11.003 PMID: 17493546

52. Matsuoka N, Patki A, Tiwari HK, Allison DB, Johnson SB, Gregersen PK, et al. Association of K121Q polymorphism in ENPP1 (PC-1) with BMI in Caucasian and African-American adults. Int J Obes (Lond). 2006; 30(2):233–7.